Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | KYNU | Q16719 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809176 | 1.00 | CTSK (0.63) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL2627396 | 0.90 | CTSK (0.62) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL29941638 | 0.90 | CTSK (0.62) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL10254381 | 0.90 | CTSK (0.62) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL10028352 | 0.89 | ALDH1A1 (0.64) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL26195471 | 0.89 | CTSK (0.64) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL13503284 | 0.89 | ALDH1A1 (0.64) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL2895983 | 0.89 | CTSK (0.64) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL265512 | 0.89 | CTSK (0.64) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL319160 | 0.89 | CTSK (0.64) | CTSKALDH1A1ALOX15CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968587-B2 | Heterocycle analogs of CAI-1 as agonists of quorum sensing in vibrio | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180078526-A1 | HETEROCYCLE ANALOGS OF CAI-1 AS AGONISTS OF QUORUM SENSING IN VIBRIO | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-03-22 | — | — | US | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078526-A1 | HETEROCYCLE ANALOGS OF CAI-1 AS AGONISTS OF QUORUM SENSING IN VIBRIO | CACNG1, VIPR1, CAP1 | CTSK 1598/4885ALDH1A1 2444/4885ALOX15 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.